- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07739121
Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations (BEACON)
Benchmarking AI for Clinical Oncology decisioNmaking (BEACON): A Prospective, Multicentre, Blinded Evaluation of Frontier Large Language Models Against Multidisciplinary Tumour Board Recommendations in Oncology Treatment Planning
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
BEACON is a prospective, multicentre, blinded benchmark using automated, criteria-based scoring. It is built on three design decisions that distinguish it from the existing literature: (i) synthetic, standardised cases remove the record-completeness variability that confounds retrospective comparisons and allow the identical input to be given to every board and every model; (ii) two independent tumour boards per localisation let human-human agreement be measured rather than assumed; and (iii) a guideline matrix, locked a priori, provides an objective anchor applied identically to human and model recommendations.
Reference standard. For each case-domain, a guideline matrix (guideline-recommended / acceptable / unsupported options per case-domain; ESMO, NCCN), locked and time-stamped before data collection, is applied identically to boards and models.
Five decision domains. Every recommendation is decomposed into D1 Intent, D2 Surgery, D3 Radiotherapy, D4 Systemic therapy (class + line), and D5 Work-up & biomarkers before any comparison.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Jérôme Lambert, MD PhD
- Telefonnummer: +33 0142499742
- E-post: jerome.lambert@u-paris.fr
Studera Kontakt Backup
- Namn: Jean-Emmanuel Bibault, MD PhD
- Telefonnummer: +33 01 56 09 34 06
- E-post: jean-emmanuel.bibault@aphp.fr
Studieorter
-
-
-
Paris, Frankrike
- Rekrytering
- Hôpital Europeén Georges Pompidou
-
Kontakt:
- Jean-Emmanuel Bibault, MD PhD
- Telefonnummer: +33 01 56 09 28 34
- E-post: jean-emmanuel.bibault@aphp.fr
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Synthetic oncology case within one of the five predefined localisations (breast, lung, urological, digestive, gynaecological).
- Complete structured schema: UICC 8th-edition stage, biomarkers, ECOG performance status, comorbidities and a standardised clinical question.
- A clinically answerable treatment-planning question that is mappable to the locked guideline matrix.
Exclusion Criteria:
- Case outside the five predefined localisations.
- Incomplete, internally inconsistent or ambiguous schema.
- Duplicate or near-duplicate of an existing case in the set.
- Question not resolvable by current guidelines.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Breast cancers
|
Two independent tumour boards per localisation (10 boards in total) issue a categorical recommendation for every synthetic case.
Where both boards agree, their consensus defines the reference standard; where they differ, the case-domain is classified as EQUIPOISE and analysed separately.
Five frontier LLMs (GPT-5.6,
Claude Fable 5, Gemini 3.1 Pro, DeepSeek V4 Pro, Llama 4 Maverick) each receive the identical structured input for every case, three times in independent sessions, under locked prompts, versions and settings.
|
|
Lung cancers
|
Two independent tumour boards per localisation (10 boards in total) issue a categorical recommendation for every synthetic case.
Where both boards agree, their consensus defines the reference standard; where they differ, the case-domain is classified as EQUIPOISE and analysed separately.
Five frontier LLMs (GPT-5.6,
Claude Fable 5, Gemini 3.1 Pro, DeepSeek V4 Pro, Llama 4 Maverick) each receive the identical structured input for every case, three times in independent sessions, under locked prompts, versions and settings.
|
|
Urological cancers
|
Two independent tumour boards per localisation (10 boards in total) issue a categorical recommendation for every synthetic case.
Where both boards agree, their consensus defines the reference standard; where they differ, the case-domain is classified as EQUIPOISE and analysed separately.
Five frontier LLMs (GPT-5.6,
Claude Fable 5, Gemini 3.1 Pro, DeepSeek V4 Pro, Llama 4 Maverick) each receive the identical structured input for every case, three times in independent sessions, under locked prompts, versions and settings.
|
|
Digestive cancers
|
Two independent tumour boards per localisation (10 boards in total) issue a categorical recommendation for every synthetic case.
Where both boards agree, their consensus defines the reference standard; where they differ, the case-domain is classified as EQUIPOISE and analysed separately.
Five frontier LLMs (GPT-5.6,
Claude Fable 5, Gemini 3.1 Pro, DeepSeek V4 Pro, Llama 4 Maverick) each receive the identical structured input for every case, three times in independent sessions, under locked prompts, versions and settings.
|
|
Gynaecological cancers
|
Two independent tumour boards per localisation (10 boards in total) issue a categorical recommendation for every synthetic case.
Where both boards agree, their consensus defines the reference standard; where they differ, the case-domain is classified as EQUIPOISE and analysed separately.
Five frontier LLMs (GPT-5.6,
Claude Fable 5, Gemini 3.1 Pro, DeepSeek V4 Pro, Llama 4 Maverick) each receive the identical structured input for every case, three times in independent sessions, under locked prompts, versions and settings.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Domain-level performance between LLM recommendations and the locked guidelines.
Tidsram: Assessed once at central scoring, after data collection (~October 2026)
|
For each recommendation domain and each LLM, proportion of LLM recommendation concordant with locked guidelines
|
Assessed once at central scoring, after data collection (~October 2026)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of recommendations carrying serious harm potential ( LLM and tumour boards)
Tidsram: Up to October 2026
|
Up to October 2026
|
|
|
Domain-level recommendation concordance between LLM and tumour-boards
Tidsram: Up to October 2026
|
Each recommendation domain, decomposed into the five decision domains and scored per domain on an ordinal scale (2 = complete concordance; 1 = partial concordance; 0 = discordance).
|
Up to October 2026
|
|
Inter-tumour board domain-level recommendation concordance
Tidsram: Up to October 2026
|
Agreement between the two independent tumour boards scored per recommendation domain
|
Up to October 2026
|
|
Equipoise rate
Tidsram: Up to October 2026
|
Proportion of case-domains where the two tumour boards give different categorical recommendations
|
Up to October 2026
|
|
Completeness
Tidsram: Up to October 2026
|
Proportion of required domains addressed (LLM and tumour boards)
|
Up to October 2026
|
|
Missingness
Tidsram: Up to October 2026
|
Proportion of critical omissions (LLM and tumour boards)
|
Up to October 2026
|
|
Intensity bias
Tidsram: Up to October 2026
|
Proportion of recommendation corresponding to over- or under-treatment
|
Up to October 2026
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Genitala neoplasmer, manliga
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Genitala sjukdomar, manliga
- Prostatasjukdomar
- Manliga urogenitala sjukdomar
- Njursjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Luftvägssjukdomar
- Matsmältningssystemets sjukdomar
- Lungsjukdomar
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Hudsjukdomar
- Bröstsjukdomar
- Sjukdomar i urinblåsan
- Hud- och bindvävssjukdomar
- Neoplasmer
- Prostatiska neoplasmer
- Lungneoplasmer
- Bröstneoplasmer
- Neoplasmer i urinblåsan
- Urologiska neoplasmer
- Neoplasmer i njurarna
- Neoplasmer i matsmältningssystemet
Andra studie-ID-nummer
- APHP261032
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .